hrp0089p1-p169 | Growth & Syndromes P1 | ESPE2018

A Novel Type of Pubertal Height, Weight, and BMI Reference, Aligned for Onset of Puberty

Albertsson-Wikland Kerstin , Niklasson Aimon , Gelander Lars , Holmgren Anton , Aronson Stefan , Sjoberg Agneta , Lissner Lauren

Context: Specific references for height, weight and BMI that consider the maturation tempo for onset of puberty are lacking worldwide.Aim: To fill the gap, by developing specific pubertal references for heightSDS, weightSDS and BMISDS, all aligned for the individual onset of puberty.Method: Reference population: a subgroup of GrowUp1990Gothenburg cohort of 1572 (763 girls) health...

hrp0089p1-p170 | Growth & Syndromes P1 | ESPE2018

Evaluating Cut-offs for Automatic Growth Screening in Swedish Children – Using the Finnish Growth Monitoring Algorithm

Gelander Lars , Niklasson Aimon , Holmgren Anton , Saari Antti , Dunkel Leo , Albertsson-Wikland Kerstin

Background: Growth charts provide excellent help to the pediatric team in identifying abnormal growth patterns. However, the evaluation is highly dependent on the skills of the clinician. A computerized automatic screening system will add quality and patient safety in finding children with disorders affecting growth. Such screening system has been developed and tested in Finland and resulted in earlier detection of growth disorders1-3.Aim: To ...

hrp0086p1-p630 | Growth P1 | ESPE2016

GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: Endogenous GH pattern is characterized by high peaks (growth signal) and low trophs (metabolic signal). Exogenous GH is given by subcutaneous injection (scGH-injection) daily at bedtime.Objective and hypotheses: To study the factors influencing intra-/interindividual variation of pharmacokinetics and pattern of scGH-injection in GH treated children.Method: One hundred and twenty eight subjects followed yearly ≤ 8 ...

hrp0086p1-p631 | Growth P1 | ESPE2016

Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?

Lundberg Elena , Andersson Bjorn , Kristrom Berit , Rosberg Sten , Albertsson-Wikland Kerstin

Background: GH-secretion rates for children ranges in pre/early puberty 0.1–11 U/24 h and during mid-puberty 4–40 U/24 h. This can be used to optimize the rhGH treatment doses in children.Objective and hypotheses: To calculated the bioavailable rhGH in relation to injected dose and compare this to GH-secretory rate in healthy children; and to investigate factors influencing bioavailability.Method: One hundred and twenty e...

hrp0082p1-d2-150 | Growth (1) | ESPE2014

Cognitive Processing Speed as a Function of GH Treatment in Short Stature Children: a Multiple Regression Analysis

Chaplin John Eric , Kristrom Berit , Jonsson Bjorn , Tuvemo Torsten , Albertsson-Wikland Kerstin

Background: Cognitive function has been shown to improve following GH treatment in adults. In children born small for gestational age (SGA) IQ scores were found to improve following 24 months of GH treatment.Objective and hypotheses: The aim was to observe cognitive function in pre-pubertal, short children with isolated GH deficiency (IGHD) or idiopathic short stature (ISS) during the first 24 months of GH treatment. Cognitive testing was carried out usi...

hrp0082p2-d1-453 | Growth | ESPE2014

New Reference for Height in Swedish Boys and Girls

Albertsson-Wikland Kerstin , Niklasson Aimon , Gelander Lars , Holmgren Anton , Nierop Andreas F M

Background: The actual Swedish growth references are based on a cohort born 1974.Objective and hypotheses: Due to secular changes there is need for new height references.Method: Material: Height measurements from birth to adult height (AH) in a cohort of healthy, Nordic and born full term 1990, 20.796 from 1647 boys, 19.202 from 1501 girls were used (ALL) and compared to both a subgroup with puberty close to mean (PHV &#17...

hrp0084p1-137 | Turner & Puberty | ESPE2015

Normalization of Puberty and Adult Height in Girls with Turner Syndrome, Randomised Trials vs Age and Dose at GH-Start

Kristrom Berit , Ankarberg-Lindgren Carina , Barrenas Marie-Louise , Nilsson Karlolof , Albertsson-Wikland Kerstin

Background: Early TS diagnosis permits early GH start and estradiol (E2) supplementation approaching adult height (AH) at normal age and within a normal range. However, higher age at diagnosis is still a challenge.Objective and hypotheses: The hypothesis from our long-term trials will result in knowledge for personalized treatment in order to obtain a psychological acceptable age at onset of puberty and still an attained AH within normal range...

hrp0084p2-219 | Bone | ESPE2015

Early Increase of the Bone Formation Marker PINP is in a Higher Degree Related to Growth Response Compared to Bone Mineralization in GH Treated Prepubertal Children

Decker Ralph , Andersson Bjorn , Swolin-Eide Diana , Magnusson Per , Kristrom Berit , Albertsson-Wikland Kerstin

Background: It has been reported that short-term increases of the bone formation markers intact amino-terminal propeptide of type I procollagen (PINP), bone-specific alkaline phosphatase (BALP) and osteocalcin display different temporal patterns. In adults, the biphasic model of GH action in bone remodelling shows that GH treatment results initially in an increased bone resorption with a concomitant bone loss, which later on is followed by increased bone formation. In children...

hrp0084p3-945 | GH & IGF | ESPE2015

As Great Intra as Interindividual Variability in Uptake of s.c. GH Injections in Longitudinally Followed GH Treated Children

Lundberg Elena , Kristrom Berit , Andersson Bjorn , Rosberg Sten , Albertsson-Wikland Kerstin

Background: The variation in uptake of daily sc GH-injections is hardly known.Objective and hypotheses: There is a considerable variability in uptake of s.c. GH-injections both within and between children.Method: 65 children used (Genotropin® pen 4/16, needle 12 mm), dose 0.08–0.14 mU/kg per day within trials: TRN 87–010; 88–080; 88–177; followed yearly two–eight times 1992–1999 (n=214). ...

hrp0094p1-162 | Growth B | ESPE2021

Evaluation of growth patterns from the Edinburgh and Gothenburg cohorts by the QEPS model

Holmgren Anton , Niklasson Aimon , Nierop Andreas F.M , Butler Gary , Albertsson-Wikland Kerstin ,

Background: The QEPS-growth-model, developed and validated in GrowUpGothenburg cohorts, used for developing growth references and investigating healthy/pathological growth, lacks external validation from other longitudinal cohorts of healthy individuals.Objective: To investigate if the QEPS-model fits the longitudinal Edinburgh growth study of another design than GrowUpGothenburg cohorts. To compare growth patterns in tw...